Blog
RSS FeedPosted by Michael Wonder on 30 Mar 2022
Cystic fibrosis: early access granted to the Kaftrio/Kalydeco combination
29 March 2022 - The High Authority for Health has authorised early access to a first treatment for children aged 6 ...
Posted by Michael Wonder on 22 Jan 2022
COVID-19: early access granted to Paxlovid as a curative treatment
21 January 2022 - In the context of very high circulation of SARS-CoV-2, the High Authority for Health (HAS) and the ...
Posted by Michael Wonder on 20 Nov 2019
French Authorities approve national reimbursement of Orkambi (lumacaftor/ivacaftor) for eligible people ages two and older with cystic fibrosis
20 November 2019 - Vertex Pharmaceuticals today announced that the French Authorities (Comité économique des produits de santé, or CEPS) ...
Posted by Michael Wonder on 11 Feb 2016
Agenda for the 17 February 2016 TC meeting
11 February 2016 - The Transparency Commission will consider the reimbursement of sonidegib diphosphate (Odomzo), emtricitabine with elvitegravir and cobicistat and ...